NORMAN — Alzheimer’s researchers are encouraged by new therapies that appear to be slowing the disease’s progression in patients with mild cases. That was the report coming from the American Neurological Association’s annual meeting in Boston this past week.
Large studies on two drugs, solanezumab and bapineuzumab, are showing promise. The two therapies remove a specific protein that is thought to inhibit brain function.
USA Today said high levels of beta amyloid are toxic to the brain in the same way high cholesterol levels damage the heart.
If the treatments pass FDA regulators, the next questions will be when to treat patients and who will pay for it. The newspaper reports some brain changes start as early as 25 years before symptoms appear.